Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Two novel biomarkers have been found to correlate with improved outcomes with immunotherapy in metastatic breast cancer and may help to identify the patients most likely to benefit from this treatment.
Cancer-related fatigue is a prevalent and potentially persistent issue among breast cancer survivors, which can prevent them from returning to their previous life well after treatment ends and they are declared free of disease.
The 2020 ESMO Breast Cancer Congress will be held as a virtual meeting, on 23-24 May.
In view of the spread of Coronavirus infections across Europe and now increasingly in France, ESMO has made the difficult but necessary decision not to proceed with the TAT Congress, due to take place 2-4 March in Paris.
For enquiries please contact us on media@esmo.org
In due consideration of the latest information on the Coronavirus outbreak, ESMO and IASLC have made the unavoidable decision to cancel the ELCC 2020 Congress, due to take place 15-18 April in Geneva, Switzerland.
TMB is actively being studied as a predictive biomarker for identifying patients who might benefit from immunotherapy but the issue of variability between assays has been raised
CXCR4 antagonist, BL-8040 modifies the tumour microenvironment
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.
